Sars-CoV2COR-DIAL-1NCT04367142
Rapid Detection of COVID-19 by Portable and Connected Biosensor
An observational study of Sars-CoV2, run by University Hospital, Lille at 1 site in France.
Trial summary
The objective of study is to estimate the sensitivity and specificity of the COR-DIAL based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of COVID-19 made by the medical team. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Sars-CoV2
- What is being tested?
- COVID-19 RT-PCR and Biosensor
- How many people
- 200 participants
- Where
- 1 siteFrance
- Study dates
- 24 Aug 2020to 2 May 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patients admitted to a Reference Health Establishment for suspicion of SARS-CoV-2
Who may be able to join
- Male or female or child without age limit
- Admitted to a Reference Health Establishment in an emergency unit, hospitalisation or intensive care unit for suspicion of SARS-CoV-2 infection, regardless of the clinical presentation and degree of severity.
- Patient to be diagnosed using a PCR test on nasopharyngeal swab.
- Social insured
Who cannot join
- Atypical or suspicious cases without a final diagnosis of COVID-19 positive or negative
- Patient refusal to participate
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept
The objective of study is to estimate the sensitivity and specificity of the COR-DIAL based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of COVID-19 made by the medical team.
- Conditions
- Sars-CoV2
- Being tested
- COVID-19 RT-PCR, Biosensor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
COVID-19 RT-PCRDiagnostic test
Nasopharyngeal swabs for COVID-19 RT-PCR
BiosensorDiagnostic test
Portable and Connected Biosensor viral
| Study group | Role | What they receive |
|---|---|---|
| positive SARS-Cov2 | 100 patients with a positive diagnosis of SARS-CoV-2 Receives: Diagnostic Test: COVID-19 RT-PCR; Diagnostic Test: Biosensor | |
| negative SARS-Cov2 | 100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team Receives: Diagnostic Test: COVID-19 RT-PCR; Diagnostic Test: Biosensor |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team
Measured: Baseline (at admission)
Secondary outcomes (1)
Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and COR-DIAL based on nasopharyngeal swabs taken on patient admission
Measured: Baseline (at admission)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2020
- Study start24 Aug 2020
- Primary completion2 May 2023
- Study completion2 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sars-CoV2Studies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Enagnon Kazali ALIDJINOU, MD, Principal investigator, University Hospital, Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04367142
- Sponsor's protocol ID
- 2020_36
- Other IDs
- 2020-A01147-32
- Acronym
- COR-DIAL-1
- Status last verified
- May 2023
- First submitted
- 27 Apr 2020
- Last updated
- 17 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept
- ClinicalTrials.gov ID
- NCT04367142
- Acronym / sponsor ID
- COR-DIAL-1 / 2020_36
- Conditions
- Sars-CoV2
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Study start
- 24 Aug 2020 (actual)
- Primary completion
- 2 May 2023 (actual)
- Study completion
- 2 May 2023 (actual)
- First posted
- 29 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of study is to estimate the sensitivity and specificity of the COR-DIAL based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of COVID-19 made by the medical team.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| positive SARS-Cov2 | – | Diagnostic Test: COVID-19 RT-PCR, Diagnostic Test: Biosensor100 patients with a positive diagnosis of SARS-CoV-2 |
| negative SARS-Cov2 | – | Diagnostic Test: COVID-19 RT-PCR, Diagnostic Test: Biosensor100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patients admitted to a Reference Health Establishment for suspicion of SARS-CoV-2
Key inclusion criteria (4 listed)
- Male or female or child without age limit
- Admitted to a Reference Health Establishment in an emergency unit, hospitalisation or intensive care unit for suspicion of SARS-CoV-2 infection, regardless of the clinical presentation and degree of severity.
- Patient to be diagnosed using a PCR test on nasopharyngeal swab.
- Social insured
Key exclusion criteria (2 listed)
- Atypical or suspicious cases without a final diagnosis of COVID-19 positive or negative
- Patient refusal to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| COVID-19 RT-PCRNasopharyngeal swabs for COVID-19 RT-PCR | Diagnostic test | negative SARS-Cov2, positive SARS-Cov2 |
| BiosensorPortable and Connected Biosensor viral | Diagnostic test | negative SARS-Cov2, positive SARS-Cov2 |
Primary outcome
Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team
Time frame: Baseline (at admission)
1 secondary outcome
Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and COR-DIAL based on nasopharyngeal swabs taken on patient admission
Time frame: Baseline (at admission)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2024.
Related trials for Sars-CoV2
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Enagnon Kazali ALIDJINOU, MD principal investigator
University Hospital, Lille
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sars-CoV2, run by University Hospital, Lille at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team (time frame: Baseline (at admission)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2024.